WuXi PharmaTech is building a new, 145,000-sq.-ft. cGMP facility in Philadelphia for the manufacture of cell therapies. This facility will contain viral vectors such as chimeric antigen receptor T cell (CAR T cell) therapies, which are T cells harvested from a patient’s body, engineered to target specific cancers, and then reintroduced into the body. The company currently has a facility for biological safety and lot release testing in Philadelphia.   This will be WuXi’s third cell th...